Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00

Axsome Therapeutics (NASDAQ:AXSM) had its price target upped by HC Wainwright from $180.00 to $190.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

AXSM has been the topic of a number of other research reports. Truist Financial lifted their price target on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Robert W. Baird upped their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Needham & Company LLC restated a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a report on Monday, January 13th. Mizuho reduced their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, December 31st. Finally, StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $132.08.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $106.46 on Friday. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $5.16 billion, a P/E ratio of -16.30 and a beta of 1.04. The business has a 50-day moving average of $93.57 and a 200-day moving average of $90.90. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $111.51.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter last year, the business posted ($1.32) EPS. On average, equities analysts anticipate that Axsome Therapeutics will post -4.72 EPS for the current year.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. acquired a new stake in Axsome Therapeutics in the second quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Axsome Therapeutics in the second quarter valued at $47,000. R Squared Ltd acquired a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $64,000. KBC Group NV raised its stake in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after purchasing an additional 385 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.